BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Zura Bio (ZURA)Zura Bio2026-06-25 13:46 ESTClinical readout

HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 5, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today

Open original release

Related news

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio to Participate in Upcoming Investor Conferences

ZURAZura Bio2026-06-25 13:46 EST

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

View all latest news

Zura Bio

Zura Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ZURAZura Bio2026-06-26 17:29 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

ZURAZura Bio2026-06-26 17:29 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-26 17:29 EST

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

ZURAZura Bio2026-06-26 17:29 EST

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

ZURAZura Bio2026-06-26 17:29 EST

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States